鉴定了一种新的有趣的BAG3调节器,能够破坏与癌症相关的途径
Dafne Ruggiero1, Eleonora Boccia1, Emis Ingenito1,2
1Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084, Fisciano, Italy.
ChemMedChem
|July 9, 2025
概括
研究人员确定了一种与BAG3有效相互作用的新型三醇化合物,通过破坏关键细胞通路,显示出显著的抗癌活性. 这一发现为开发向癌症治疗提供了一个有希望的新途径.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 针对BAG3蛋白的新型调节剂的发现对于开发新的抗癌药物至关重要.
- 现有的BAG3调制器的数量有限,这凸显了对新的化学支架的需求.
研究的目的:
- 确定和描述具有抗癌潜力的新型BAG3调节剂.
- 探索三醇支架在准BAG3.3中的治疗效用.
主要方法:
- 公司内部复合图书馆的高通量选.
- 生物物理测定和计算研究用于结构改进.
- 对亡和蛋白质静止的复合效应的评估.
主要成果:
- 发现了一种新型的三醇化合物 (化合物2),与BAG3.3有强烈的相互作用.
- 化合物2对癌细胞表现出显著的细胞毒性活性.
- 该化合物的机制涉及破坏BAG3相关途径,影响亡和蛋白质稳定.
结论:
- 组合2代表了BAG3调制器领域的重大进步.
- 三醇支架在开发更有效的抗癌药物方面具有相当大的潜力.
- 对三醇衍生物的进一步探索可能会导致新的癌症治疗方法.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Intrinsic Apoptotic Pathway
6.9K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.9K


